

Further Reading

FSRH Clinical Effectiveness Unit. *Quick starting contraception*. Faculty of Sexual and Reproductive Healthcare. 2010 Sep. Available online at: <https://www.fsrh.org/standards-and-guidance/documents/ceuguidancequickstartingcontraception/>

Declaration

Dr Terri Foran was commissioned by Healthed for this article. The ideas, opinions and information presented are solely those of the author. The advertiser does not necessarily endorse or support the views expressed in this article.

The author's competing interests statement can be viewed at www.healthed.com.au/monographs.

References

1. Bracken MB. *Oral contraception and congenital malformations in offspring: a review and meta-analysis of the prospective studies*. *Obstet Gynecol*. 1990 Sep; 76(3 Pt 2): 552–557
2. Westhoff C, Kerns J, Morroni C, Cushman LF, Tiezzi L, Murphy PA. *Quick start: novel oral contraceptive initiation method*. *Contraception*. 2002 Sep; 66(3): 141–145
3. Westhoff C, Morroni C, Kerns J, Murphy PA. *Bleeding patterns after immediate vs. conventional oral contraceptive initiation: a randomized, controlled trial*. *Fertil Steril*. 2003 Feb; 79(2): 322–329
4. Oakley D, Sereika S, Bogue EL. *Oral contraceptive pill use after an initial visit to a family planning clinic*. *Fam Plann Perspect*. 1991 Jul-Aug; 23(4): 150–154
5. Brache V, Cochon L, Duijkers IJ, Levy DP, Kapp N, Monteil C et al. *A prospective, randomized, pharmacodynamic study of quick-starting a desogestrel progestin-only pill following ulipristal acetate for emergency contraception*. *Hum Reprod*. 2015 Dec; 30(12): 2785–2793
6. FSRH Clinical Effectiveness Unit. *Quick starting contraception*. Faculty of Sexual and Reproductive Healthcare. 2010 Sep. Available online at: <https://www.fsrh.org/standards-and-guidance/documents/ceuguidancequickstartingcontraception/>

Competing interests statement:

Dr Terri Foran was commissioned by Healthed for this article. The ideas, opinions and information presented are solely those of the author. The advertiser does not necessarily endorse or support the views expressed in this article.

Over the past 5 years Dr Terri Foran has had financial relationships (educational development, conference presentation, member of advisory board/consultancy) with a number of pharmaceutical companies which manufacture products for contraception. These companies include Bayer, MSD, Pfizer and Teva.